In a post by Laura Bobolts on Linkedin, it says, “The inaugural ✨Oncology Pharmacists Connect✨ conference in Austin, TX was such a hit! 🙌 So many great speakers reviewed the latest ASCO abstracts. I loved learning what people really thought of the trials, I mean really really thought…
🔸Nivo-AVD is an up and coming cost effective option in HD per SWOG S1826
🔸ADAURA’s screening & limited cross-over questions the exact OS benefit of adjuvant osimertinib in NSCLC
🔸NALIRIFOX (Liposomal irinotecan, oxaliplatin, 5-FU/LV) NOT studied vs FOLFORINOX (with generic irinotecan) in pancreatic, questioning the true value — NCCN even states it “adds considerably more expense”
🔸Pharmacists are enthusiastic about X-7/7 (doesn’t it sound exciting like a fast & furious movie!🍿): fixed dose 7 on/7 off capecitabine in metastatic breast

It was such an honor to be on the Steering Committee for this event & represent OncoHealth with my managed care insights. Huge thank you Pharmacy Times Continuing Education™ (PTCE) crew for all your hard work creating such a cutting edge post-ASCO event, Hematology/Oncology Pharmacy Association (HOPA) for the amazing collaboration, and Ryan Haumschild PharmD, MS, MBA for doing such a phenomenal job as always chairing this event!

I can’t wait for next year!!! It was so great meeting so many trail blazing oncology pharmacists!”

Source: